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Introduction: To compare a schedule with cyclic withdrawal (CW) of interferon beta
(IFN-b) 1b, respect to the full regimen (FR), in relapsing-remitting MS (RR-MS).
Methods: Participants were randomly assigned to CW or FR schedule and monthly
monitored with brain MRI scans for 12 months (three of run-in and 9 of treatment). CW
schedule included drug withdrawal for 1 month after two of treatment for a total of three
quarters over the 9-month treatment period. The assessing neurologist and the expert
neuroradiologists were blind. After the blind phase of the study all participants took their
indicated disease modifying therapies in a prospectively planned, open-label extension
phase (up to 120 months).
Results: Of 60 randomized subjects 56 (29 in FR and 27 in CW group) completed
the single-blind phase: the two groups were comparable, except for a non-significant
difference in the number of contrast-enhanced lesions (CEL) at the end of run-in.
The two-sided 90% CI for the ratio between median number of cumulative CEL
was 0.29–1.07, allowing to significantly reject the null hypothesis of a ratio ≥1.2
and to meet the primary end-point of non-inferiority (the threshold and the ratio
between median were chosen according to the non-normal distribution of the data).
The differences (CW vs. FR) were also non-significant for secondary end points:
mean cumulative number of T2-weighted new and enlarging lesions (3.48 ± 5.34
vs. 3.86 ± 6.76); mean number and volume (cm3) of black holes (1.24 ± 1.61
vs. 2.71 ± 4.56; 489.11 ± 1488.12 vs. 204.48 ± 396.98); number of patients
with at least an active scan (21 vs. 22); mean relapse rate (0.52 ± 0.89 vs. 0.34
± 0.66), relapse risk ratio adjusted for baseline variables (2.15 [0.64–7.18]), EDSS
score (1.0 [1–1.56] vs. 1.5 [1–1.78]), proportion of patients with antibodies anti-IFN
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(5 [21%] vs. 8 [36%]). Fifty-four patients (27 for each study arm) completed the open-label
phase. The annualized RR, EDSS, proportion of patients shifting to progressive disease
and hazard ratio of shifting, adjusting for baseline covariates, were comparable between
the two study groups.
Conclusions: A calendar with CW was non-inferior than FR at the beginning of IFN-b
therapy, and may not affect the long-term outcome.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT00270816
Keywords: relapsing-remitting multiple sclerosis, interferon beta 1b, non-inferiority, cyclic withdrawal, contrast-
enhanced lesions, black holes
INTRODUCTION
Relapsing remitting multiple sclerosis (RR-MS) has become
manageable thanks to a wide range of new treatments (1).
However, these therapies last for decades and raise issues
of safety, reduction in life quality, treatment adherence, and
healthcare expenditure (2).
Furthermore, inflammation, neurodegeneration, and
metabolic modifications co-exist and all need therapeutic
intervention in MS; however, none of the approved disease
modifying therapies (DMT) has been proven to tackle them
all. The increasingly shared view is that combining therapies
with different mechanisms of action may target the complex
pathophysiology of the disease (3–5).
Hence, given the characteristics of available treatments,
and within the perspective of facilitating the development of
combination therapies, new regimens that reduce the treatment
burden represent an unmet need in MS.
Work in our group using serial transcriptome analysis in
peripheral blood mononuclear cells (PBMC) of patients treated
with interferon beta (IFN-b) showed that gene expression
changes are more pronounced during the 1st weeks of treatment,
with a clear tendency to return to baseline levels 2–3months after
treatment initiation (6). This result provided the rationale for the
design of a treatment regimen that includes cyclic withdrawals
(CW) of treatment with IFN-b 1b. This schedule may in principle
maintain the biological impact that is gradually lost due to the
homeostatic response, be less cumbersome for patients and less
expensive for the healthcare system. We therefore tested the
hypothesis of non-inferiority of a schedule based on CW of IFN-
b 1b compared to the canonical, full regimen (FR) in persons
with RR-MS.
Abbreviations: ARR, annualized relapses rate; BH, black holes; cBHs, chronic
black holes; CDMS, clinically definite multiple sclerosis; CELs, contrast enhancing
lesions; CI, Confidence Interval; CPE, cytopathic effect; CW, cyclic withdrawal;
D-MEM, Dulbecco’s modified eagle’s medium DMT, disease modifying therapies;
EDSS, Expanded Disability Status Score. CW, cyclic withdrawal; EMC,
encephalomyocarditis virus; FCS, fetal calf serum. FLAIR, fast fluid- attenuated
inversion-recovery FR, full regimen; HR, Hazard Ratio; Gd, gadolinium; IFN-b,
interferon beta; IQR, Interquartile Range; LOCF, last observation carried forward;
MRI, magnetic resonance imaging; MS, Multiple sclerosis NAB, Neutralizing
antibodies; PBMC, peripheral blood mononuclear cells; RR, risk ratio; RR-MS,
relapsing remitting multiple sclerosis; SE, spin-echo; T1W, T1-weighted; T2W,
T2-weighted; TRU, 10-fold reduction unit.
PATIENTS AND METHODS
Standard Protocol Approvals,
Registrations, and Patient Consents
The present single-blind, phase-IV, randomized clinical study
was performed at the Center for Experimental Neurological
Therapies, Ospedale S. Andrea-site, “Sapienza” University
of Rome, and Università Cattolica, Fondazione Policlinico
Universitario “A. Gemelli,” Rome, Italy. The study was registered
at the ClinicalTrial.gov (NCT00270816). The trial was conducted
according to Good Clinical Practice guidelines and the
Declaration of Helsinki. The protocol was approved by the Ethics
Committee of Ospedale S. Andrea, “Sapienza” University of
Rome and each patient provided written informed consent.
Patients
Patients with RR-MS (7) were consecutively screened and
enrolled between November 2006 and November 2008. The
following were considered as inclusion criteria: age between
18 and 50 years (inclusive); no steroid treatment in the 2
months prior to the study and no previous exposure to any
DMT. Exclusion criteria were: systemic diseases; pregnancy,
inability to agree on the use of contraception for women of
childbearing potential and breast-feeding, inability to undergo
magnetic resonance imaging (MRI).
Protocol
The study design included a 3-month run-in period (months 1–
3) and a 9-month treatment period (months 4–12). At the end
of the run-in, patients were 1:1 randomized to receive either
IFN-b 1b every other day consecutively (FR arm) or to CW arm
(drug withdrawal for 1 month after two of treatment for a total
of three quarters over the 9-month treatment period). Patients
of the CW arm stopped IFN beta-1b 3 times, at months 6, 9,
and 12. A list of randomization numbers and corresponding
treatment numbers was computer-generated before the start of
the study. A 2-physician-treating and assessing-model was used:
the treating physician supervised drug administration, evaluated
adverse events, and safety; the assessing physician evaluated
outcome measures and was blind.
A prospectively planned, extension of the trial was conducted
up to 120 months, during which the patients remained under the
FR standard schedule of IFN-b 1b, or were shifted to the DMT
that their neurologist in charge considered indicated.
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FIGURE 1 | CONSORT flow diagram.
Procedures
At first visit each patient underwent a clinical examination to
rate disability with the Expanded Disability Status Score (EDSS)
scale (8), performed routine blood tests, any required test to
rule out MS mimickers, electrocardiogram, and brain MRI scan.
Thereafter, each patient underwent monthly clinic visit andMRIs
for the first 12 months, and every 6-month clinical with or
without imaging assessment till month 120.
Clinical relapses were defined as the appearance of new
symptoms or worsening of previous symptoms/signs associated
with changes in the neurological examination lasting longer
than 24 h in the absence of fever, infections or any other acute
process that could be responsible for neurological worsening.
Adverse events were defined as any untowardmedical occurrence
regardless of its causal relationship to the study treatment. The
severity of the adverse events was graded as: mild (minimal or
no required treatment and no interference with the patient’s
daily activities); moderate (low level of inconvenience or concern;
may require therapeutic measures and cause some interference
with functioning); severe (interruption of a patient’s usual daily
activities and requirement of systemic drug therapy or other
treatment; usually incapacitating); life-threatening (immediate
risk of death).
At the above specified time points all participants were imaged
with gadolinium (Gd)-enhanced MRI of brain to calculate the
number of contrast enhancing lesions (CELs) and the other
outcome measures (see below). MRI was performed using a 1.5-
T magnet (Philips Gyroscan NT 1.5).The magnet underwent
several upgrades during the study period and care was taken
that none of these upgrades affected the sequences in use.
T2-weighted (T2W) spin-echo (SE) (TR = 2,000ms; TE =
20/90ms), fast fluid-attenuated inversion-recovery (FLAIR) (TR
= 6,000ms; TE = 150ms) and T1-weighted (T1W) SE (TR
= 550ms; TE = 12ms) sequences were acquired in the axial
plane with 5-mm contiguous slices, and a field of view (FOV) =
240mm, matrix = 256 X256. The hardcopy was analyzed by two
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experienced neuroradiologists working in pairs (when there was a
disagreement a third senior neuroradiologist reviewed the images
and a final consensus was reached). They were blind and detected
the number of Gd-enhancing lesions, T2-hyperintense lesions,
and T1-hypointense lesions. The number of chronic black holes
(BH) on T1WMRI was assessed according to Bagnato et al. (9).
Neutralizing antibodies (NAB) status was evaluated
with a bioassay based on the cytopathic effect (CPE) of
encephalomyocarditis virus (EMC) on human lung carcinoma
cells (A549) as previously described (10, 11). The assay was
performed prior to study entry and at the end of the 9-month
treatment phase. The neutralization titer of serum samples was
calculated according to Kawade’s formula (12), and expressed
in 10-fold reduction unit (TRU) (13). A level of >20 TRU was
considered as the threshold for positivity.
Outcomes Measures
Group (CW vs. FR) differences in the cumulative number of
CELs over the first 9-month period was defined as the primary
end point. Secondary end points included: group differences in
cumulative number of new and enlarging T2-weighted lesions,
number of patients with at least an active scan, relapse rate,
number, and volume of BH, EDSS score, and proportion of NAB
+ patients. The outcome measures of the open label phase were
the following: annualized relapses rate (ARR), EDSS, proportion
of patients shifting to progressive MS [defined according to
Lublin et al. (14) and Lublin et al. (15)].
Statistical Analysis
Group differences at study entry were assessed using a t-test
for continuous variables and a chi-square test for categorical
variables. For continuous variables, median and Interquartile
Range (IQR) were also calculated. When the variable distribution
was non-normal according to Shapiro-Wilk test, the two groups
were compared performing a non-parametric K-sample test on
the equality of medians.
At the end of the single-blind phase of the trial, mean,
standard deviation, median, IQR, and the range values were
calculated for the primary and secondary endpoints, separately
for CW and FR patients. For the primary outcome, we established
to compare the number of CELs between the two regimens
thorough the mean difference or the ratio of medians according
to the normal or non-normal distribution of the data. In case of
normality distribution of the data, we considered 8.1 as the mean
number of CELs observed in the FR regimen in a previous work
of our group (observed by Pozzilli et al. in a period of 6 months)
(16) and operatively set a difference of 1.5 cumulative CELs for
non-inferiority of the CW vs. the FR schedule, and 2 cumulative
CELs of standard deviation. In this scenario, we rejected the null
hypothesis with a significance level of 0.05 if the upper limit of the
two-sided 90% confidence interval (CI) of the difference between
the means of the 2 regimens was < 1.5 CEL (17, 18). To compute
a one-sided testing procedure for the difference of the means,
with an alpha error = 5% and a study power = 0.80, a sample
size of 46 patients was required. Thirty patients per group were
TABLE 1 | Baseline demographic and clinical metrics, along with MRI outcome
measures after run-in.
Patient characteristic FR (n = 29) CW (n = 27) P-value
AGE, YEARS
Mean ± SD 37.07 ± 7.25 35.70±8.03 0.507a
Median (IQR) 39 (33.50–40.50) 37 (30–40)
SEX
M/F 12/17 10/17 0.789b
DISEASE DURATION, MONTHS
Mean ± SD 48.45 ± 61.43 82.89 ± 91.54 0.130c
Median (IQR) 15 (6–65) 48 (10–156)
RELAPSE NUMBERd
Mean ± SD 2.25 ± 1.29 2.38 ± 1.33 0.714a
Median (IQR) 2 (1–3) 2.31 (1–3)
EDSS SCORE
Mean ± SD 1.49 ± 1.28 1.25 ± 0.73 0.941c
Median (IQR) 1.5 (1–1.75) 1 (1–1.5)
CUMULATIVE NUMBER OF GD-ENHANCING LESIONS AT MRI
Mean ± SD 5.66 ± 11.58 2.81 ± 4.05 0.486c
Median (IQR) 1 (0–3) 0 (0–4)
CUMULATIVE NUMBER OF NEW AND ENLARGING T2-WEIGHTED
LESIONS AT MRI
Mean ± SD 2.93 ± 5.61 1.74 ± 3.94 0.483c
Median (IQR) 1 (0–2) 0 (0–2)
NUMBER OF PATIENTS WITH AT LEAST
AN ACTIVE SCAN DURING RUN-IN
N 20 18 0.854b
(n = 24)e (n = 25)e
BLACK HOLES NUMBERf
Mean ± SD 2.58 ± 4.46 1.20 ± 1.80 0.879c
Median (IQR) 0 (0–4) 0 (0–2)
Range 0–18 0–7
BLACK HOLES–OVERALL VOLUMEf (cm3)
Mean ± SD 222.06 ± 442.83 586.92 ± 1523.14 0.831c
Median (IQR) 0 (0–208.62) 0 (0–371.93)
Range 0–1659.39 0–6673.33
at-test for continuous variables.
bChi-square test for categorical variables.
cNon-parametric Wilcoxon rank-sum test (for variables with non-normal distribution).
dBefore study entry.
eThe baseline demographic and clinical characteristics of this subgroup were not different
from those of the 7 patients lost for this analysis.
fAfter run-in.
recruited to account for a drop-out rate of 20%. Power analyses
were performed using StudySize software (version 2.0).
In case of non-normal distribution of the data, we
operationally considered a non-inferiority threshold for the
ratio of median of 1.2, assuming a standard deviation on elog
Scale of 0.3. In this case, recruiting 30 patients per group allow to
get a power of 0.90 for a one sided 95% CI. The null hypothesis
was that the ratio of the median of the CW group on the median
of the FR group was ≥ 1.2 and therefore the non-inferiority was
demonstrated if the upper limit of the two sided 90% CI for the
ratio of medians was lower than 1.2. Normality was tested using
the Shapiro-Wilk test.
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FIGURE 2 | Two-sided 90%CI for the ratio between median number of cumulative Gd-enhancing lesions at MRI observed in the two regimens. Maximum ratio of 1.2
lesions was set for the one-tailed test with a significance level of 0.05. At month 12 median of the cumulative number of Gd-enhancing lesions at MRI was 1 (0–9) in
CW vs. 3 (0–10) in FR patients.
For the secondary endpoints, we calculated the relapse risk
ratio (RR) using a Poisson model adjusted for the baseline
variables (gender, age, disease duration, relapse number before
study entry, EDSS, and MRI metrics), and performed a non-
parametric K-sample test on the equality of medians for the
EDSS score and the MRI metrics, that showed a non-normal
distribution. During the single-blind phase of the trial an
intention to treat analysis was performed adopting a LOCF (last
observation carried forward) method.
During the open-label extension of the trial, we compared
the annual relapse rate and the EDSS score between CW and
FR groups performing a non-parametric K-sample test on the
equality of medians, because of the non-normal distribution
of the above variables. The proportion of patients who shifted
to a progressive disease was compared using a chi-square
test. Individual follow-up started with the beginning of the
open label phase and finished at the end of the follow-up
period (120 months), death, loss at follow-up, or shifting to a
progressive disease.
RESULTS
Patients Disposition and Characteristics
Figure 1 depicts eligibility assessment, patients screening,
and inclusion. Table 1 reports baseline demographic and
clinical characteristics of patients, as well as MRI metrics
after the run in period. All the variables, including those
showing a non-normal distribution, were balanced between the
two groups.
Outcome Measures
At the end of the trial, we verified that the normality was
not satisfied for the primary outcome. Therefore, we tested
the non-inferiority comparing the medians of the two groups.
The median number of cumulative Gd-enhancing lesions at
MRI was comparable between the two study arms, meeting
the primary end-point: median 3 and IQR (0–10) for FR vs.
median 1 (0–9) for CW; p = 0.496. Specifically, there was
a 95% chance that the median number of cumulative Gd-
enhancing lesions with the CW regimen was at most 1.2 times
the median number of cumulative Gd-enhancing lesions with
the FR schedule (Figure 2). The ratio of the median of the
CW group on the median of the FR group and its relative two
sided 90% CI was 1 (0.29; 1.07), allowing to significantly reject
the null hypothesis of a ratio ≥1.2, and to confirm the non-
inferiority of the CW regimen. Data related to the secondary
endpoints of the first 9-month treatment period are summarized
in Table 2. All secondary endpoints were met, although the study
was not powered for any of them. The relapse RR, adjusted for
baseline covariates, was comparable between CW and FR group
(RR = 2.15, 95% CI: 0.64–7.18). Likewise, the mean number of
cumulative new and enlarging T2-weighted lesions, the number
of patients with at least an active scans, the number and volume
of black holes and the median values of EDSS score did not show
significant differences between the two study arms (respectively,
p = 0.820; p = 0.865; p = 0.666; p = 0.626; and p = 0.201). The
proportion of NAB+ patients was similar between the two study
arms: 8 (36%) in FR group and 5 (20%) in CW; p = 0.33 (data
not shown).
The open-label extension phase lasted between 8 and 10
years, depending upon individual patient recruitment date. In
this phase, all patient who remained on IFN-b 1b took the FR,
while others shifted to the DMT that their neurologist deemed
indicated. The shifting to a second-line treatment occurred in a
minority of cases (7/27 in both groups). Results of the open-label
phase, summarized in Table 3, showed no difference between
CW and FR study arms in the median of annual relapses
rate (p = 0.276), the median of EDSS score (p = 0.691), and
the proportion of patients shifting to a progressive phase of
disease (p= 0.715).
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TABLE 2 | Secondary end points after 9 months of treatment.
Outcomes FR (n = 29) CW (n = 27) P-value
CUMULATIVE NUMBER OF GD-ENHANCING LESIONS AT MRI
Mean ± SD 9.52 ± 17.01 5.85 ± 9.42 0.496c
Median (IQR) 3 (0–10) 1 (0–9)
CUMULATIVE NUMBER OF NEW AND ENLARGING T2-WEIGHTED
LESIONS AT MRI
Mean ± SD 3.86 ± 6.76 3.48 ± 5.34 0.820c
Median (IQR) 1 (0–2) 2 (0–4)
NUMBER OF PATIENTS WITH AT LEAST
AN ACTIVE SCAN
N 22 21 0.865b
RR (95%CI)a
RELAPSES
Mean ± SD 0.34 ± 0.66 0.52 ± 0.89 2.15 (0.64; 7.18)




Mean ± SD 1.76 ± 1.33 1.33 ± 0.72 0.201
Median (IQR) 1.5 (1–1.78) 1 (1–1.56)
Range 0–6.5 0–3
(n = 24)c (n = 25)c
BLACK HOLES–NUMBERd
Mean ± SD 2.71 ± 4.56 1.24 ± 1.61 0.666
Median (IQR) 0 (0–4) 1 (0–2)
Range 0–18 0–5
Black HOLES–OVERALL VOLUME (cm3)d
Mean ± SD 204.48 ± 396.98 489.11 ± 1488.12 0.626
Median (IQR) 0 (0–199.08) 0 (0–441.07)
Range 0–1380.44 0–7357.59
aRelapse risk Ratio (RR) were obtained from Poisson model adjusting for the baseline
variables (gender, age, disease duration, number of relapses before study entry, EDSS
score, MRI metrics). After adjusting for covariates we analyzed 49 subjects with
complete information.
bNon-parametric Wilcoxon rank-sum test (for variables with non-normal distribution).
cThe baseline demographic and clinical characteristics of this subgroup were not different
from those of the 7 patients lost for this analysis.
dAt month 12 of the study.
No major adverse event was recorded throughout the trial.
During the single-blind phase and the open-label extension of the
trial the frequency and the nature of adverse events were within
the established profile of IFN-b 1b, or the DMT that the patients
shifted to, without differences between CW and FR study arms.
DISCUSSION
Our pilot work compared two IFN-b 1b regimens in RR-MS and
showed non-inferiority of a calendar with therapeutic holiday
with respect to the approved schedule. The outcome measures
proved to be comparable between the two study arms for both the
clinical-MRI end-points, and the development of NAB to IFN-b
during the blind phase of the trial.
TABLE 3 | Outcomes measures of the open label phase.
Outcomes FR (n = 27) CW (n = 27) p-value
ANNUAL RELAPSE RATE
Mean ± SD 0.20 ± 0.21 0.40 ± 0.73 0.276a
Median (IQR) 0.14 (0–0.37) 0.25 (0–0.50)
Range 0–0.7 0–3.5
EDSS SCORE
Mean ± SD 2.42 ± 2.14 2.40 ± 2.29 0.691a
Median (IQR) 1.5 (1–3.5) 1.5 (1–3.5)
Range 0–7 0–7
SHIFTING TO A PROGRESSIVE DISEASE
N (%) 4 (0.14) 5 (0.18) 0.715b
aNon-parametric Wilcoxon rank-sum test (for variables with non-normal distribution).
bChi-square test for categorical variables.
The clinical metrics gathered over the open-label phase lasting
up to 10 years (during which most of patients remained under
continuous IFN-b therapy, or were shifted to the DMT that their
neurologist in charge considered indicated) were also comparable
between the two groups, suggesting that beginning IFN therapy
with a cyclic dose variation should not affect the long-term
clinical progression of MS. Our finding points to the possibility
of an IFN-b schedule with better therapeutic index and cost-
effectiveness ratio, at least in cases with relatively benign disease,
taking into account that there are ∼30% of patients stable on
IFN-b long-term treatment. The estimated saving for a year of
the therapy with 1-month holiday every quarter (as in our trial
design) is about 5,000 euros/patient (or 20,000 dollar/patient in
US). These improvements also open new perspectives for the
design of combination therapies, a much-needed step in a disease
with multiple mechanisms of damage, and a timely advancement
now that treatments directed against the neurodegenerative
component of the disease are emerging (19). This perspective
contributes to the current relevance of our study, although
the present landscape of the first-line DMT, that include oral
drugs, has actually restricted the indications of injectable DMT.
In fact, interferons remain a relevant option within available
treatments, as witnessed also by the development of new IFN-b
formulations aimed at reducing the frequency of the injections
(20). In this context, if therapeutic holidays should prove
feasible also with this class of IFNs, administered once every 2
weeks, the convenience of these injectable therapies would be
further increased.
Previous work suggested an increased efficacy of IFN-b at
higher dose in contrasting disease activity (21–23). Moreover, in
a daily clinical setting, a switch to higher dose of IFN-b may be in
principle prescribed to obtain a better control of disease course,
though with uncertain outcomes on the risk of further relapses
or increased disability (24). In accord with a substantial amount
of pre-clinical and clinical research in conditions other than MS
(25), we now suggest that the therapeutic holidays sustain the
biological impact of IFN-b over time (in spite of the lower overall
dose) by periodically interrupting feedback mechanisms that
are anticipated in chronic treatment regimens (the homeostatic
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response during chronic treatments is well-documented also at
the clinical level by the reduction of the flu-like syndrome after
the beginning of IFN-b therapies, of gastrointestinal symptoms
and flushing during dimethyl fumarate treatment and of other
side-effects with various other drugs). A study on the continuous
vs. intermittent therapy for chronic hepatitis C with interferon
alfa-2a supports this interpretation (26). Notably, the block
of the homeostatic response was not as strong as to imply a
clinically significant resurgence of the flu-like syndrome at the
beginning of each new cycle of treatment. In fact, though we
did not plan formal questionnaires to compare the quality of
life between the two study arms, and we had no adherence
problems in FR group, virtually all participants experiencing the
CW regimen reported satisfaction for the regular withdrawal.
Overall, these results are in line with expectations based on
our transcriptomics study in PBMC from IFN-treated patients,
that prompted this pilot trial. It showed both homeostatic
responses to IFN-b administration (that we used to design
the dynamics of drug holiday), and sustained and lasting
effects on up- or down-regulated genes, that antagonize some
pathogenic loops of MS (6). Previous work on drug holiday for
other DMT in MS are rare, with contrasting or disappointing
results (27–29); however, this trial suggests to deepen temporal
dynamics underpinning their biological effects in MS course,
with the aim of reducing the treatment burden or favoring
combination therapies.
Concerning the potential limitations of this trial, we chose to
leave patients under CW regimen on a “true” therapeutic holiday:
they were not given placebo during themonth of IFNwithdrawal,
thus remaining un-blinded on their treatment schedule. In fact,
blindness of neuroradiologists and the assessing neurologist
was deemed sufficient considering the study end points. On
the other hand, a sort of nocebo effect due to expectation of
lower treatment response to the CW regimen did not produce
measurable changes, being met the end points of non-inferiority.
Another point of caution is the small sample size of the trial;
it allowed us to obtain statistical significance, but warns against
definitive conclusions and may require confirmative studies.
This is in line with the pilot nature of our study, that was
designed to minimize the possibility that loss of efficacy might
occur in a larger population under CW regimen. The open-
label phase of the study has the expected limitations of a trial
long-term extension: non-prospective design, possibly selective
dropout rate, un-blinded assessment and poor monitoring,
underpowered sample size. The loss of only 2 patients in FR
group at long-term follow-up, and the fact that the shifting
to a second-line treatment occurred in a minority of cases
in both study arms indicate the validity of the long follow-
up we chose. Also, the analysis of the categorical results of
the open-label part of the study, that were adjusted for the
baseline characteristics of participants, might help mitigate, at
least in part, the above potential shortcomings. However, the data
coming from the unblinded trial phase should be interpreted
with caution.
Randomized, non-inferiority trials are rare in MS likely
because of the challenges that these studies raise, as recently
elucidated (30). Though exploratory, this trial may be relevant
in the MS therapeutic field, providing information that might
improve the schedule of IFN-beta administration in persons
with RR-MS. This information is relevant for clinical practice
(31) and for the design of poly-therapies [an approach that is
beginning to be tested: reference (32), and ClinicalTrials.gov-
NCT02907177] aimed at combating the various mechanisms
of damage that compose the complex pathophysiology
of MS.
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